What is HC Wainwright’s Estimate for Immunic Q1 Earnings?

Immunic, Inc. (NASDAQ:IMUX) – Analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Immunic in a report issued on Monday, March 2nd. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.20) per share for the quarter, down from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunic’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at ($0.20) EPS and FY2030 earnings at ($0.08) EPS.

Several other research analysts have also weighed in on IMUX. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. D. Boral Capital cut their price objective on Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a report on Friday, February 13th. Brookline Capital Acquisition raised Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, Roth Mkm assumed coverage on Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $6.00.

Immunic Price Performance

NASDAQ IMUX opened at $1.07 on Wednesday. The firm has a market capitalization of $139.59 million, a price-to-earnings ratio of -1.53 and a beta of 1.46. The company has a 50 day simple moving average of $0.72 and a 200-day simple moving average of $0.76. Immunic has a 52-week low of $0.51 and a 52-week high of $1.35.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02).

Institutional Investors Weigh In On Immunic

A number of large investors have recently bought and sold shares of IMUX. Qube Research & Technologies Ltd bought a new position in Immunic during the third quarter valued at about $29,000. Two Sigma Investments LP bought a new stake in shares of Immunic during the 3rd quarter worth about $52,000. HB Wealth Management LLC acquired a new position in shares of Immunic during the 3rd quarter valued at about $81,000. Seven Fleet Capital Management LP acquired a new position in shares of Immunic during the 4th quarter valued at about $83,000. Finally, Virtu Financial LLC bought a new position in shares of Immunic in the 3rd quarter valued at approximately $99,000. 51.82% of the stock is currently owned by institutional investors.

Key Immunic News

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS forecasts (Q3 & Q4 2026 and FY2026/FY2027 improvements) and kept a Buy rating, which supports a constructive near‑term view on reducing expected losses. Details here: MarketBeat: IMUX coverage
• Neutral Sentiment: Management will present at investor conferences in March (Leerink Partners Global Healthcare Conference, March 8–11). Conference participation increases investor access and could catalyze new analyst or institutional interest but does not guarantee clinical or financial news. Immunic to Participate in Investor Conferences in March
• Negative Sentiment: HC Wainwright cut its price target from $8 to $5.0 (still a Buy) and trimmed several longer‑term EPS forecasts (notably FY2028 and FY2029), which can exert downward pressure on the stock because it reduces upside expectations and signals lower long‑term profitability. Coverage of the PT cut here: HC Wainwright Lowers Immunic Price Target to $5.00
• Negative Sentiment: HC Wainwright also lowered some near‑term quarter estimates (Q1 and Q2 2026 were revised lower), increasing short‑term execution risk and potential for additional downside if upcoming results miss the revised figures. Summary reporting: Benzinga coverage

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.